Helixgate

Helixgate

Uncategorized

STAT+: What does Akeso’s primo plenary spot say about its survival data?

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

I’m suffering from spring allergies + a nasty head cold this week. Not fun.

Mystery cloaks an ASCO plenary lung cancer survival result

The runup to next month’s annual meeting of the American Society of Clinical Oncology has started, and a good bit of the Wall Street chatter and speculation is centered on the Akeso-Summit Therapeutics drug ivonescimab.

Continue to STAT+ to read the full story…

Read More

Published

on

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

I’m suffering from spring allergies + a nasty head cold this week. Not fun.

Mystery cloaks an ASCO plenary lung cancer survival result

The runup to next month’s annual meeting of the American Society of Clinical Oncology has started, and a good bit of the Wall Street chatter and speculation is centered on the Akeso-Summit Therapeutics drug ivonescimab.

Continue to STAT+ to read the full story…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

STAT+: Trump’s obesity drug plan creates a temporary Medicare program that may be hard to end

WASHINGTON — Weight loss drugs will be available to adults 65 and older in Medicare for the first time next month, thanks to a government program that’s supposed to be temporary. It may be difficult to end it.

Medicare is prohibited by law from paying for obesity drugs. The Trump administration is circumventing that law by making the drugs available via a demonstration program.

Initially, Medicare had hoped to push private Medicare insurers to voluntarily cover the drugs via a three-year program called BALANCE, which would have started following a short transitional period. But insurers balked, so the federal government is instead extending the transitional coverage program, called Bridge, until the end of next year.

Continue to STAT+ to read the full story…

Read More

Published

on

WASHINGTON — Weight loss drugs will be available to adults 65 and older in Medicare for the first time next month, thanks to a government program that’s supposed to be temporary. It may be difficult to end it.

Medicare is prohibited by law from paying for obesity drugs. The Trump administration is circumventing that law by making the drugs available via a demonstration program.

Initially, Medicare had hoped to push private Medicare insurers to voluntarily cover the drugs via a three-year program called BALANCE, which would have started following a short transitional period. But insurers balked, so the federal government is instead extending the transitional coverage program, called Bridge, until the end of next year.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

Neumora discards depression asset, lays off staffers after pair of late-stage flops

Published

on

Neumora Therapeutics is laying off 35% of workers after its most advanced asset failed a pair of Phase 3 studies, sending the biotech’s stock spiraling early Monday.

Continue Reading

Uncategorized

Germany rethinking drug price reforms after Lilly, Boehringer withdraw investments: Reuters

Published

on

Weeks after Boehringer Ingelheim and Eli Lilly retracted billions of dollar in German commitments, the nation’s government is reportedly changing a contentious element of its planned healthcare reforms.

Continue Reading
Advertisement

Trending